Business Model Breakdown
How Viking Therapeutics Inc Makes Money
VKTX
Market Cap
$3.6B
Employees
48
The Short Version
Viking Therapeutics is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for metabolic and endocrine disorders. It currently does not generate product revenue. Its core business model involves advancing promising drug candidates, particularly VK2735 for obesity, through rigorous clinical trials (currently Phase 2/3). The ultimate goal is to achieve regulatory approval, after which it would either commercialize the drugs directly, license them to larger pharmaceutical partners for sales and distribution, or potentially be acquired by a larger entity. Revenue generation would then come from product sales, royalties, milestone payments, or acquisition premiums.
Where the Revenue Comes From
No current product revenue (~0%)
Future potential: Product sales, licensing fees, milestone payments (~100% of future revenue)
Who buys: Currently, clinical trial participants and scientific community. Future customers would be patients suffering from metabolic and endocrine disorders, and potentially larger pharmaceutical partners.
Why It Works (Competitive Advantages)
- ✔Dual GLP-1/GIP agonist mechanism for potentially superior efficacy.
- ✔Promising clinical data (Phase 2 injectable and oral) suggesting best-in-class potential compared to current market leaders.
- ✔Development of both injectable and oral formulations, offering broader patient accessibility and market penetration.
- ✔Strong intellectual property protection for VK2735.
Economic Moat: Narrow (Intangible Assets/IP (patents covering VK2735 composition of matter and methods of use), Switching Costs (for patients on an effective, well-tolerated treatment regimen))
What Our Analysis Says
DVR Score as of June 3, 2026
Viking Therapeutics maintains strong 10x growth potential, with its lead asset VK2735 (a dual GLP-1/GIP agonist) continuing to show compelling clinical promise in the lucrative metabolic disorder market. Recent additional positive Phase 2 data for the oral formulation, showing up to 12.2% weight loss, reinforces its potential as a best-in-class option and strengthens its competitive position. While the Q1 2026 EPS miss and a significant 247% YoY increase in net loss to $158.3 million are financial headwinds, these are common for pre-revenue clinical-stage biotechs investing heavily in R&D. The company's substantial cash reserves (>$800M estimated from training data post-recent raises) provide a solid runway, mitigating immediate financial risk. Upcoming Phase 3 initiation for the injectable form acts as a strong catalyst. The score is a slight adjustment from the previous 90, reflecting the heightened burn rate while acknowledging the strengthening clinical data.